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Abstract
Background: Soluble growth factors present in the microenvironment play a major role in tumor development,
invasion, metastasis, and responsiveness to targeted therapies. While the biochemistry of growth factor-dependent
signal transduction has been studied extensively in individual cell types, relatively little systematic data are available
across genetically diverse cell lines.
Results: We describe a quantitative and comparative dataset focused on immediate-early signaling that regulates
the AKT (AKT1/2/3) and ERK (MAPK1/3) pathways in a canonical panel of well-characterized breast cancer lines. We
also provide interactive web-based tools to facilitate follow-on analysis of the data. Our findings show that breast
cancers are diverse with respect to ligand sensitivity and signaling biochemistry. Surprisingly, triple negative breast
cancers (TNBCs; which express low levels of ErbB2, progesterone and estrogen receptors) are the most broadly
responsive to growth factors and HER2
amp cancers (which overexpress ErbB2) the least. The ratio of ERK to AKT
activation varies with ligand and subtype, with a systematic bias in favor of ERK in hormone receptor positive (HR
+)
cells. The factors that correlate with growth factor responsiveness depend on whether fold-change or absolute
activity is considered the key biological variable, and they differ between ERK and AKT pathways.
Conclusions: Responses to growth factors are highly diverse across breast cancer cell lines, even within the same
subtype. A simple four-part heuristic suggests that diversity arises from variation in receptor abundance, an ERK/AKT
bias that depends on ligand identity, a set of factors common to all receptors that varies in abundance or activity
with cell line, and an “indirect negative regulation” by ErbB2. This analysis sets the stage for the development of a
mechanistic and predictive model of growth factor signaling in diverse cancer lines. Interactive tools for looking up
these results and downloading raw data are available at http://lincs.hms.harvard.edu/niepel-bmcbiol-2014/.
Keywords: Breast cancer, Microenvironment, Receptor tyrosine kinases, Signal transduction, Growth factors
Background
Receptor tyrosine kinase (RTK) signaling is an important
form of cell-cell communication involving 58 human re-
ceptors falling into 20 families [1]. Each RTK binds to one
or more soluble or membrane-bound ligands (growth
factors) that promote the formation of receptor homo-
and hetero-oligomers and assembly of multi-component
signaling complexes (except that the ErbB2 RTK has
no known ligand and normally functions as a hetero-
oligomer). Receptor-bound signaling proteins activate
‘immediate-early’ signaling by MAPK, PI3K/AKT, and
other kinase cascades and regulate motility, differentiation,
adhesion, proliferation and cell survival. The biochemistry
of RTK signaling proteins has been characterized exten-
sively, but relatively little systematic data are available on
the diversity of signaling responses mediated by these pro-
teins across cell lines.
Many RTKs are mutated, over-expressed, or dysregu-
lated in cancer and a large number of anti-cancer drugs
targeting RTKs are in use or in development [2]. In
some cases these drugs bind primary oncogenic drivers
such as ErbB2, which is overexpressed in the HER2
amp
breast cancer subtype [3], or ErbB1, which is mutated in
non-small cell lung cancer [4]. In other cases, RTKs
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http://www.biomedcentral.com/1741-7007/12/20promote oncogenesis or alter drug sensitivity by respond-
ing to paracrine and autocrine ligands present in the
microenvironment, produced either by the tumor itself or
by the surrounding stroma. For example, the presence of
ErbB ligands in colorectal cancer is correlated with in-
creased survival following treatment with cetuximab, a
therapeutic antibody targeting EGFR [5,6]. Conversely, the
presence of ErbB ligands promotes resistance to ErbB
therapy in other cancers [7-9] and HGF production by
stromal cells is a factor in the preexisting resistance of
BRAF-V600E melanomas to vemurafinib [10]. The latter
observation is one motivation for clinical development of
drugs inhibiting the HGF receptor cMet [10].
To date, systems-level studies of immediate-early signal
transduction have focused primarily on increasing the
number of proteins analyzed. For example, mass spec-
trometry has revealed the kinetics of phosphorylation of
approximately 1,000 substrates in EGF-treated HeLa cells
[11], and reverse phase lysate arrays have provided data
on approximately 50 substrates in five cell lines exposed
to seven growth factors [12], and on six isogenic lines
ectopically over-expressing individual RTKs [13]. Analysis
of receptor-mediated signal transduction in a particular
tumor cell line is subject to the criticism that no line is
representative of human cancer. However, generalizing
across cell lines is complicated by the occurrence of large,
but poorly characterized, variability. Recent genomic and
expression profiling experiments have demonstrated the
value of systematically analyzing such variability and it
appears that a significant fraction of the complexity of
specific human cancers can be captured using banks of
genetically diverse cell lines [14,15].
In this paper we analyzed growth factor responsiveness
in a canonical collection of 39 breast cancer cell lines of
the NCI-ICBP43 set, whose genotypes span many of the
mutations observed in primary disease [16]. The data
comprised the phosphorylation levels of ERK (MAPK1/3)
and AKT (AKT1/2/3) kinases following exposure to 15
different growth factors at two doses and three time
points, as well as the abundance and phosphorylation
levels of over 20 RTKs [17]. The goals of the analysis were
to: (i) characterize the diversity of response and determine
how it mapped to clinical subtypes, (ii) identify factors
that controlled the magnitude and duration of ligand re-
sponse, and (iii) generate a simple means to look up and
compare ligand-response data that have hitherto been un-
available or scattered across the literature. We found that
breast cancer cell lines exhibit highly diverse responses to
growth factors with lines belonging to the “triple negative”
(TNBC) subtype being the most broadly responsive and
HER2
amp lines the least. The magnitude of ligand re-
sponses appeared to be determined by four primary
factors: the identity of the ligand, the abundance of
the cognate RTK, regulators common to all receptors
but different for AKT and ERK and differing in levels
or activity with cell type, and indirect negative regula-
tion mediated by the ErbB2 receptor. The significance of
these factors varies depending on whether fold-change
or absolute response is regarded as the biologically sig-
nificant feature.
Results
We generated a multidimensional growth factor response
dataset with axes corresponding to cell line, ligand iden-
tity, ligand dose, exposure time, and downstream target
(see Additional file 1: Table S1). To facilitate visualization
of the data we constructed a set of node-edge graphs (one
per cell line) in which the diameter and shading of a node
is proportional to the logarithm of the steady state protein
abundance and basal phosphorylation level, respectively.
The weight of an arrow connecting ligands to pAKT (red)
or pERK (blue) denotes the magnitude of the response
based on the maximal value across time points at the
highest dose. Under the starvation conditions used for
these assays, basal phosphorylation levels are likely to
reflect autocrine signaling, the presence of activating
mutations in signaling proteins, or, in the case of cells ex-
pressing high levels of ErbB2, receptor auto-activation
[18]. Edges linking ligands to receptors are a representa-
tion of published binding data (see Additional file 2:
Table S2) and differences in affinity are not depicted.
Comparing MCF7, BT-20, and MDA-MB-453 cells
(Figure 1A-C; node-edge graphs for all lines are found in
Additional file 3 and at a dedicated website [19]), we see
that pERK was induced by many more ligands than
pAKT in MCF7 cells, pAKT and pERK were induced to
a similar extent by multiple ligands in BT-20 cells, and
only FGF-1/2 and ErbB ligands (EGF, BTC, HRG and
BTC) elicited a significant yet muted response in MDA-
MB-453 cells. Thus, breast cancer cell lines are broadly
responsive to growth factors, but the extent of pERK and
pAKT induction varied dramatically with the line. The
connection between RTK level and ligand responsiveness
was not immediately obvious (compare the size of the
RTK nodes to the thickness of blue and red edges): for ex-
ample, MCF7 and MDA-MB-453 expressed similar levels
of insulin receptor, but only MCF7 cells had a significant
response to insulin at the level of pAKT induction.
Overall, approximately 60% of cell-ligand combina-
tions resulted in significant induction of pERK (where
significant means a signal two standard deviation above
the mean of untreated control cells) and approximately
50% of combinations resulted in pAKT induction. Li-
gands that bind to ErbB receptors were the most broadly
active (every tested ErbB ligand elicited a significant re-
sponse in at least 35 lines), followed by FGF-1/2, HGF,
and IGF-1/2, consistent with the known importance of
these ligands in breast cancer biology. pERK induction
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Figure 1 (See legend on next page.)
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http://www.biomedcentral.com/1741-7007/12/20ranged from statistically insignificant to more than
600-fold in CAMA-1 cells exposed to HRG. More-
over, induction of pERK was transient in some cell lines
(for example, MCF-7, MDA-MB-453; Figure 1D) and
sustained in others (for example, CAMA-1, BT20). Even
within a single ligand family, substantial differences in
relative responsiveness were observed: HRG and EGF
induced pERK to the same degree in BT-20 and T47D
cells, but HRG was much more potent than EGF in
CAMA-1 and MCF-7 cells (Figure 1D, E). Differences
were also observed with respect to which downstream
kinases were activated: BT-20 and T47D cells were highly
responsive to EGF at the level of pERK and pAKT, whereas
EGF induced only pERK in CAMA-1 and MCF-7 cells
(Figure 1D, F). This did not arise because the AKT path-
way is defective in CAMA-1 and MCF-7 cells since HRG,
another ErbB ligand, induced pAKT in both cell lines.
Relating signaling features to cancer subtype
In the clinic, breast cancers are classified into HER2
amp,
hormone receptor positive (HR
+), or TNBC subtypes
based on the expression levels of the ErbB2 tyrosine kin-
ase and the estrogen and progesterone nuclear hormone
receptors (ER/PR). We found that TNBC cell lines as
a group (Figure 1G) exhibited relatively low expres-
sion of receptors other than EGFR and had low basal
pAKT or pERK activity compared to the other sub-
types (Figure 1H, I). However, in these cells, pAKT
and pERK were more responsive to a wider range of
growth factors than in any other subtype (Figure 1J).
This included responsiveness to HRG, despite the fact
that HRG functions via ErbB2-containing receptor het-
erodimers and ErbB2 is notionally absent in TNBCs (in
fact, ErbB2 is present at 10
4 to 10
5 molecules per
cell, a high level for an RTK, albeit lower than the
10
6 to 10
7 molecules per cell observed in HER2
amp
cells). As expected, HER2
amp cell lines exhibited the
highest expression of ErbB2 and this correlated with
high basal pErbB1-4, pERK and pAKT (Figure 1H,
Additional file 4: Figure S1). In cells of this subtype,
only ErbB ligands induced a significant response, and
this was generally modest, relative to TNBC cells, as
measured by fold-change in activity (Figure 1K). Fi-
nally, HR
+ cell lines were characterized by higher levels of
ErbB3, FGFR4, and IGF1R than cell lines from other sub-
types (Wilcoxon’s P= 0.0015, P=0. 01 4a ndP=0. 02 1,re -
spectively), strong responsiveness to FGF1/2 and HRG
(Figure 1I), and by a bias of ligand responses toward pERK
(Figure 1L).
Time and dose-dependence of response
We used clustering to determine which characteristics of
immediate-early signaling are most variable across our
dataset, and whether they correlate with cell line, ligand
identity, or receptor family. Unsupervised k-means clus-
tering (with k = 4) of the time-series data identified tra-
jectories that correspond to sustained, transient, late, or
no response (Figure 2A; Additional file 5). These clusters
are similar to trajectories previously identified by ana-
lysis of phospho-mass spectrometry, ELISA, and reverse
phase lysate array data obtained from one or a few cell
lines [11-13,20]. We found that approximately 50% of all
significant ligand responses were sustained and the re-
mainders were split equally between transient and late
responses (Additional file 6: Figure S2A). The responses
in the sustained cluster were significantly stronger than
those in other clusters (Additional file 6: Figure S2B, C).
Neither dose nor downstream target (that is, pERK or
pAKT) were major determinants of temporal class, but
the identity of the ligand was: induction of pERK and
pAKT by ErbB ligands was usually sustained (Figure 2B,
first column) whereas induction of pAKT by IGF/INS
ligands was either sustained or late (Figure 2B, second col-
umn). In contrast, FGF-1/2 ligands were most likely to in-
duce transient responses (Figure 2B, third column). Fewer
cell lines were responsive to the other ligands tested, and
significant responses were split roughly equally among
sustained, transient, and late (Figure 2B, fourth column).
Comparing response data between the two doses
tested, we found that pERK was maximally responsive to
(See figure on previous page.)
Figure 1 Landscape of signaling responses across breast cancer cell lines. (A-C) Node-edge graphs of (A) MCF7 (A),B T - 2 0(B), and MDA-MB-453
(C) depicting induction of pERK (blue arrows) and pAKT (red arrows) by different ligands. The arrows’ thickness denotes the maximum induction across
all time points and doses, normalized for each target across all cell lines and ligands. Gray arrows denote non-significant responses (less than
two standard deviations above the control). Outer and inner circles represent basal measurements where the diameter is proportional to
the logarithm of the expression level and shading to the logarithm of the phosphorylation level; data were normalized across all cell
lines. pFGFR1-4 were not measured. Gray outer circles and labels denote expression levels below the detection threshold and their diameter denotes
the minimal circle size. Lines show which ligands bind which receptors (Additional file 2: Table S2). (D-F) Fold-change in pERK (D-E) or pAKT (F) levels
following exposure of cells to EGF (D, F) or HRG (E). Trajectories for six specific cell lines are highlighted in color; all other trajectories are represented
in gray. (G-I) Average node-edge graphs for each breast cancer subtypes: TNBC (G), HER2
amp (H),a n dH R
+(I). Edges and nodes have the same mean-
ing as in (A) except that circle size, intensity of shading, and edge width are proportional to the interquartile mean across lines of the subtype.
(J) Fraction of cells of each subtype showing significant pERK or pAKT responses following exposure to ErbB, FGF, IGF/INS, or HGF ligands
at 1 ng/ml. Wilcoxon’sr a n k - s u mP-values are shown. (K) Distribution of the cell line mean fold-change following stimulation at 100 ng/ml
of the same ligands as in (J). (L) Distribution of cell line median pathway bias of the same ligands as in (J).
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http://www.biomedcentral.com/1741-7007/12/201 ng/ml EGF in some cell lines (for example, BT20,
MCF7, T47D and HCC-1954; Additional file 6: Figure S2D),
but in other lines responses increased between 1 ng/ml
and 100 ng/ml EGF (MDA-MB-453), and in yet other
cases (CAMA-1) responses were observed only at the
higher ligand concentration. Classifying response into four
groups based on dose (Additional file 6: Figure S2E-F;
Additional file 5) revealed that ErbB and FGF ligands were
split between the groups ‘equal’ response and ‘increased at
the highest dose’, whereas HGF, IGFs, and insulin were
generally active at ‘100 ng/ml only’ (Figure 2C, D). Sensi-
tivity to low ligand doses did not necessarily coincide with
strong activation at high dose, but it was strongly corre-
lated with ligand identity. This implies that ligand identity,
rather than cell type or downstream pathway, is the main
determinant of low-dose responsiveness (Additional file 6:
Figure S2G). This contrasts with data on the magnitude of
the response, in which there is substantial variability from
line to line (Figure 2E-F). For each downstream target we
identified ligands that generally show strong (dark gray) or
weak (light gray) responses. ErbB ligands and HGF elicit
strong responses for both the ERK and AKT pathways. In
contrast, IGF-1 elicited a strong response only at the level
of pAKT and FGF-1 at the level of pERK. We summarize
this data in reference tables that encode the magnitude of
response, the kinetic clusters and the sensitivity classes for
pAKT (Figure 3A) and pERK (Figure 3B).
Factors controlling the relative magnitude of pERK and
pAKT responses
To characterize the selectivity of receptors for downstream
pathways, we computed a “pathway bias” based on the
maximum pAKTand pERK responses for each ligand (note
that responses for the two kinases were scaled so they could
be compared directly; in the absence of scaling, pERK ex-
hibited higher fold-changes). We found that whereas EGF
elicited symmetric pERK or pAKT induction, the FGF-1 re-
sponse was heavily biased towards pERK, and the response
of IGF-1 was biased to pAKT (solid lines in Figure 4A and
distributions in Figure 4B). Ona v e r a g e ,l i g a n d sf r o mt h e
same family exhibited a similar pERK-pAKT bias (with
HRG being an exception among ErbB ligands; Figure 4C),
but these averages obscure the fact that pERK and pAKT
responses were only weakly correlated across cell lines
(Spearman’s ρ=0.30, P=0.03, Figure 4D), making the path-
way bias for a given ligand remarkably variable. In contrast,
fold-change pERK activation by different ligands was highly
correlated within a cell line (Spearman’s ρ=0.66, P=4 .0·
10
−6,F i g u r e4 E )a n dt h es a m ew a st r u eo fp A K T( S p e a r -
man’s ρ=0.58, P=1. 2·10
−4, Figure 4F). Thus, one or more
factors common to all RTKs within a given cell line appear
to play a significant role in pERK inducibility and a different
set of factors control pAKT.
Ligand responses are commonly reported as the ratio of
the peak to basal levels and several studies have concluded
that such “fold-change” response is the determining factor
in cellular phenotype [21,22]. In other cases, however, the
absolute signal strength following stimulation determines
whether a threshold can be overcome [23]. In the case
of pERK fold-change following EGF stimulation, we ob-
served no correlation with ERK protein levels, but EGFR
levels were well-correlated (Figure 5A; Pearson’sr=0 . 4 5 ,
P=0.004). Unexpectedly, basal pErbB2 and pERK levels
were negatively correlated with pERK fold-change
(Pearson’s r=-0.45, P =0 . 0 04 ) . T his s ug ges ts t h at, for
fold-change induction of pERK by EGF, EGFR is a
positive regulator, pErbB2 a negative regulator and
ERK level does not matter. The absolute level of in-
duced pERK behaves differently, exhibiting little correl-
ation with pERK or pErbB2 levels, but strong positive
correlation with total EGFR level (Figure 5B). These
trends are observed across ligands, such as EGF, HRG,
HGF, PDGF, and SCF, for which there is a single primary
receptor (Figure 5E). The correlation is not significant
in the case of ligands such as FGF-1/2, and we specu-
late that this reflects the binding of FGF ligands to mul-
tiple FGF receptors.
In the case of pAKT fold-change in cells exposed to
the ErbB2/3 ligand HRG, no correlation was observed
with AKT, pAKT, or pErbB2 levels, but ErbB3 levels
were positively correlated (Figure 5C). Absolute levels of
induced pAKT levels were positively correlated with
ErbB3 levels, and negatively with pErbB2 and basal
pAKT levels (Figure 5D). Basal pErbB2, therefore, ap-
pears to play a different role in regulation of ERK and
AKT. In retrospect, this difference can be discerned by
examining time course data (illustrated in Figure 5A, C
for EGF and HRG). Basal pAKT levels were highly variable
(See figure on previous page.)
Figure 2 Ligands elicit different response kinetics and exhibit distinct dose-response behavior. (A) Clustered response trajectories (red:
sustained; blue: transient; off-white: late). Black lines represent the median response and colored zones the interquartile range; dashed lines
depict 10% and 90% quantiles. (B) Distribution of all responses by ligand family and downstream target for ErbB ligands, IGF/INS ligands, FGF-1/2
and all remaining ligands (data for 100 ng/ml are shown). (C-D) Distribution of sensitivity classes by ligands for pERK (C) and pAKT (D): ‘Equal’
means that the fold-change response at low dose is at least 75% of the high dose response; ‘100 ng >1 ng’ means that low dose response is
statistically significant but less than 75% of the high dose response; off-white means only the high dose response is significant. (E-F) Distribution
of fold-change response by ligand, clustered by strength of the pERK (E) or pAKT (F) response at high ligand levels. Black lines represent the
median, shaded zones the interquartile range, dashed lines the 5% and 95% quantiles, and dots the outliers. Darker gray is used for the clusters
with the strongest responses.
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http://www.biomedcentral.com/1741-7007/12/20across cell lines and correlated with pAKT levels post-
induction: the higher the baseline the higher the absolute
induced response and vice versa. This pattern was not
observed for pERK: basal levels of pERK are generally
low and fold-change is high. Similar differences be-
tween pAKT and pERK were observed for other ligands
that predominantly bind to a single RTK (Figure 5E, F).
Thus, indirect negative regulation by ErbB2 is not as im-
portant for pAKT as for pERK and receptor level is the
major factor determining pAKTfold-change.
The IGF/INS ligands are a striking exception to this
rule. Fold-change of pAKT following exposure of cells to
IGF-1 did not correlate with levels of IGF1R, but it was
strongly negatively correlated with pErbB2 (Figure 6A).
Even when cell lines were classified into IGF-1 responsive
and non-responsive classes (independently of the magni-
tude of the response), no enrichment was observed with
IGF1R levels (Figure 6B). This stands in contrast to most
other ligands (Additional file 7: Figure S3) for which cells
with high receptor levels are significantly more likely to
respond. A possible explanation is the unusually strong
negative correlation with basal pErbB2 levels, as il-
lustrated in Figure 6C by a plot of pAKT induction
by IGF-1 relative to IGF1R and basal pErbB2 levels
(Figure 6C). Note that pAKT could be strongly induced
in these cells by one or more other ligands, showing
that there was no intrinsic defect in AKT signaling.
We speculate that the connection between IGF re-
sponsiveness and IGF1R levels may be obscured by
the interaction of IGF1R with ErbB2 [24,25] or by the
presence of IGF binding proteins that are known to mod-
ify IGF responses (reviewed in [26]) and that have been
linked to resistance to anti-ErbB therapy [24,27]. Strong
cross-talk between IGF1R and ErbB2 may explain why
over-expression of IGF1R induces resistance to the anti-
ErbB2 antibody trastuzumab (Herceptin) [28].
(See figure on previous page.)
Figure 3 Summary of ligand responses across all cell lines. Data for pAKT (A) and pERK (B) in which each subplot shows the results by
ligand and cell line. The upper bar is colored according to the sensitivity class (as in Figure 2C, D), the black bars show the maximal fold-change
response for 1 ng/ml (left) and 100 ng/ml (right), and the color of the lower bar corresponds to the kinetic cluster for 1 ng/ml (left) and 100 ng/ml
responses (right; color coded as in Figure 2A, B). Cell lines are grouped by subtype and ligands by family.
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In this paper we describe a systematic analysis of RTK
inducibility in a collection of breast cancer cell lines
previously shown to span a significant fraction of the
genetic variation observed in human disease. Each ex-
amined cell line expresses multiple RTKs at levels that
vary from the limit of detection (ca. 100 molecules
per cell) to over 10
7 molecules per cell. In general,
the levels of RTKs are not highly correlated with each
other and even HER2
amp cell lines, which are defined
by over-expression of ErbB2, are divergent with re-
spect to the expression and basal phosphorylation levels
of other RTKs [17]. Thus, each cell line in our collection
has a unique RTK fingerprint. These profiles as well as
characteristics of the ligand responses are accessible
on an interactive website along with the underlying
data [19].
Sensitivity to ErbB1-4 ligands is a dominant feature of
the breast cancer cell lines we examined: all 39 lines ex-
hibited a statistically significant response to at least one
ErbB ligand (EGF, EPR, BTC, or HRG) and 31 of the 39
lines responded to all four ligands. ErbB receptors are ubi-
quitously expressed in epithelial cells and breast cancers
originate primarily from epithelial ductal or lobular linings
[29]. However, it is striking that HER2
amp lines, which
express the highest levels of ErbB2, are quite insensitive
to exogenous ligand: high ErbB2 levels correlate negatively
with fold-responsiveness of pERK to growth factors
such as the ErbB2/3 ligand HRG. In addition, pAKT re-
sponsiveness to IGF ligands and insulin is strongly
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http://www.biomedcentral.com/1741-7007/12/20negatively correlated with ErbB2 levels. In marked con-
trast, TNBC cells, which are notionally “negative” for
ErbB2, are highly responsive not only to HRG but to
ErbB ligands in general.
Other ligands to which breast cancer cells commonly
respond include FGFs, IGF/INS, and HGF. Responsive-
ness to SCF and PDGF is observed more sporadically, but
can be as strong as responses to ErbB ligands when the
cognate receptor is present. In general, responsiveness
within the same family of ligands is highly correlated,
likely because such ligands can bind overlapping sets of
receptors. TNBC cells exhibit the greatest fold-change re-
sponsiveness to ErbB ligands, FGFs, IGF/INS, and HGF,
and they also account for the preponderance of respon-
siveness to SCF and PDGF. It is tempting to speculate that
one of the reasons TNBC tumors respond poorly to tar-
geted therapies [30] is that they are sensitive to diverse
ligands present in the microenvironment, many of which
have been implicated in drug resistance [7-10]. In con-
trast, HER2
amp cancers are relatively insensitive to their
microenvironment and are among the most treatable
breast cancers. Few antibody therapeutics other than those
against ErbB receptors have proven effective in breast can-
cer and this might be a matter not only of the importance
of ErbB2 in HER2
amp cells, but also the down-regulation
of other signaling pathways in these cells. It nonetheless
seems plausible that identifying the subset of HR
+ and
TNBC cells responsive to IGFs, FGFs, and HGF might
serve as means to identify those sensitive to therapeutic
intervention with anti-receptor antibodies other than tras-
tuzumab. For example, a subset of TNBC tumors might
be sensitive to the inhibition of the c-Kit and PDGFR
receptors.
Determinants of ligand responsiveness
The available data is as of yet insufficient for construc-
tion of a mechanistic model of the responsiveness of
breast cancer cell lines to growth factors. We therefore
propose a four-factor heuristic (Figure 7) which serves
as a compact summary of our findings and can be used
to predict the probable behavior of cell lines not in our
collection. For example, from applying this heuristic we
would expect an HR
+ cell line with a high level of cMet
to have a dose-sensitive response to HGF that is strongly
skewed toward pERK.
The first factor in the heuristic is the abundance of the
cognate receptor: fold-change, absolute response levels,
and likelihood of response all correlate positively with
receptor abundance. The exceptions to this rule are
IGF/INS ligands, for which receptor levels and ligand re-
sponsiveness do not correlate. The second factor is lig-
and and receptor identity, which appears to specify
whether pERK or pAKT is most strongly induced: ErbB
ligands and HGF generally induce both pERK and
pAKT, whereas FGF1/2 are ERK specific and IGF/INS
are AKT specific. However, ligand-induced pERK/pAKT
ratios vary significantly from one cell line to the next.
This appears to involve a third set of factors, which
comprises response determinants that are common to
all RTKs in a particular cell line, but act differently on
ERK and AKT pathways. These factors are largely un-
known, but might include adapter proteins, phosphatases
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http://www.biomedcentral.com/1741-7007/12/20and so on, but it appears that these factors vary in
abundance with subtype (for example, HR
+ lines are
biased toward high pERK response). The fourth and
most unexpected factor is an “indirect negative regu-
lation” by ErbB2: expression levels of pErbB2 nega-
tively correlate with pERK fold-change for all ligands
examined and are a dominant factor for IGF/INS re-
sponse at the level of pAKT. Ligand-induced absolute
pERK levels are not correlated with pErbB2, however,
so the impact of the indirect negative regulation by
pErbB2 signaling depends on whether fold-change or
absolute level is the critical biological feature. More-
over, for all but IGF/INS, the phenomenon is reversed
for pAKT: pErbB2 and basal pAKT levels (the latter
of which can also be increased by PI3K/PTEN muta-
tions, Additional file 8: Figure S4) are positively cor-
related with absolute pAKT levels following ligand
treatment, but not with fold-change. Several factors
are noteworthy by their absence as response determi-
nants: these include absolute levels of ERK or AKT
(presumably they are present in excess), and basal RTK
phosphorylation (except in the aforementioned case of
pErbB2), implying that even high autocrine activation
does not block responsiveness to additional, exogen-
ous ligand.
Conclusions
Looking forward, mechanistic analyses are needed to
understand how the wide diversity of network activities
observed in a panel of breast cancer cell lines arises
from the action of common sets of signaling proteins.
Ascertaining the biochemical basis of indirect negative
regulation by ErbB2 is also likely to be worthwhile,
since our data imply that the high responsiveness of
HER2
amp tumors to anti-receptor therapy may be a
function not only of the addiction to the ErbB2 onco-
gene, but also of the suppression of other signaling path-
ways that might function as resistance mechanisms in
other tumor types. This would constitute a new con-
cept in therapeutic design. Finally, further analysis of
RTK expression, basal activity, and network inducibil-
ity, particularly in TNBC, may reveal possibilities for
biomarker guided use of targeted drugs in blocking
oncogenic pathways or resistance mechanisms in sub-
sets of tumors.
Methods
NCI-ICBP43 breast cancer cell lines were obtained dir-
ectly from the ATCC (product 90-4300 K), confirmed to
be Mycoplasma-free, and only early passage cultures
were used. Only 39 cell lines were used for this work
since four cell lines (DU-4475, HCC-2218, HCC-2157
and HCC-1599) were non-adherent and, therefore, not
suited to our measurement methodology. Cells were
plated to achieve approximately 75% confluence follow-
ing growth in complete media for 24 h and then starved
in serum-free media for 18 h (Additional file 1: Table
S1). Cells were either lysed immediately or exposed to
growth factors (diluted and stored according to the man-
ufacturer’s recommendation; Additional file 1: Table S1)
at a final concentration of 1 ng/ml or 100 ng/ml for 10,
30, and 90 minutes then lysed. Basal expression and phos-
phorylation levels of RTKs were measured using ELISA
assays (Additional file 1: Table S1 for details). The levels of
induced phospho-Erk1/2 (Thr202/Tyr204; pERK) and
phospho-AKT (Ser473; pAKT) served as proxies for the
activation of the MAPK and PI3K/AKT pathways and
were also measured using ELISA assays.
Basal expression and phosphorylation levels were nor-
malized using recombinant standards and all measure-
ments below the level of detection were set to the value
of the detection threshold. The ligand responses were
measured in duplicate and averaged in the log10 domain.
Responses with values less than two standard deviations
above the mean of the controls were considered to be
non-significant (corresponding to approximately 1.2-fold
change). For the calculation of pathway bias, the pAKT
response was linearly scaled by a factor of 2.386 to
minimize the Cramér-Von Mises distance between the
distribution of pERK and pAKT fold-change responses.
A detailed description of data collection and processing
can be found in Niepel et al. [17] and all data can be ob-
tained at a dedicated website [19].
Induced pAKT level
Fold change
Sensitivity
Absolute level
pErbB2
pErbB2
Induced pERK level
Fold change
Sensitivity
Absolute level
Response bias
PI3K/PTEN
Receptor level Ligand ID
Basal pERK
Basal pAKT
Factor common to pAKT
Factor common to pERK
Figure 7 Flow chart of dependencies between basal levels
and induced levels. This is a heuristic summarizing the primary
determinants of cellular response to ligands at the level of pAKT and
pERK. See text for details.
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